01
2024-07
KX-826 Androgen receptor antagonist
KX-826 is a topical androgen receptor (AR) antagonist, the world's first AR antagonist for the treatment of alopecia areata to enter registrational Phase III clinical trials.
17
2024-06
Suzhou, June 17, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Company has completed the first subject enrollment in the phase II clinical trial in China of its in-house developed androgen receptor proteolysis targeting chimera (“PROTAC”) compound GT20029 for the treatment of acne.
05
2024-06
KX-826 Received The INCI Designation
June 5, 2024-Kintor Pharmaceutical Limited announced that KX-826 received the INCI designation.
24
2024-05
Suzhou, May 24, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the clinical trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of male adult androgenetic alopecia (“AGA”) in China (the “Clinical Trial”) was cleared by the National Medical Products Administration (the “NMPA”) recently.
21
2024-04
GT20029 China Phase II Trial For AGA Reached Primary Endpoint
April 21, 2024-Kintor Pharma announced that GT20029 China Phase II Trial For AGA Reached Primary Endpoint.
02
2024-04
AACR 2024 Foreight | Three Oncology Studies From Kintor Pharma Selected
Three oncology studies from kintor pharma selected 2024 American Association of Cancer Research Annual Meeting.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn